Stocks To Cash In On The $35 Billion NASH Dash
Non-alcoholic steatohepatitis (NASH) is expected to become the leading cause of all liver transplants by 2020 – and there is currently no approved treatment for…
Big Pharma
The 21st Century Cures Act: How Investors Can Profit From This Potential “Boon For Big Pharma”
Today’s article notes that it takes almost $1 billion to bring a new drug to market, stifling competition and allowing drug companies to charge Americans…